Next-generation sequencing identifies a novel ELAVL1-TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208.

Authors :: Tron AE
Keeton EK
Ye M
Casas-Selves M
Chen H
Dillman KS
Gale RE
Stengel C
Zinda M
Linch DC
Lai Z
Khwaja A
Huszar D
Source :: Leukemia & lymphoma [Leuk Lymphoma] 2016 Dec; Vol. 57 (12), pp. 2927-2929. Date of Electronic Publication: 2016 May 17.
Publication Year :: 2016

Subjects :: Cell Line, Tumor
Drug Resistance, Neoplasm genetics
Gene Expression Regulation, Leukemic drug effects
High-Throughput Nucleotide Sequencing
Humans
Leukemia, Myeloid, Acute pathology
Protein Kinase Inhibitors therapeutic use
Biphenyl Compounds therapeutic use
ELAV-Like Protein 1 genetics
Leukemia, Myeloid, Acute drug therapy
Leukemia, Myeloid, Acute genetics
Oncogene Proteins, Fusion genetics
TYK2 Kinase genetics
Thiazolidines therapeutic use

Full Text Access

Tools